US Approval Delay For Green Cross But Long Term Strategy Intact
Green Cross has hit a bump in its journey to commercialize an immunoglobulin product in the US, but analysts say the approval delay will not be a significant obstacle to its longer term North American strategy.
You may also be interested in...
Leading South Korean pharma firm GC Pharma realigns R&D priorities and resources and changes US strategy amid delayed approval of its immunoglobulin product.
GC Pharma, formerly known as Green Cross Corp., is set to move on to the next stage of its ongoing globalization scheme with the completion of a biomanufacturing facility in Canada. Joon Soo Ryu, its vice president of office of corporate strategy, talks to Scrip about the leading Korean pharma’s North American strategy, including how it is approaching the market differently versus its Korean peers.
Keeping Track: Approvals For Xultophy, Soliqua And Darzalex; NDAs From Intarcia And GSK; Complete Response For Green Cross
The latest drug development news and highlights from our FDA Performance Tracker